Key Insights

Highlights

Success Rate

79% trial completion

Published Results

41 trials with published results (19%)

Research Maturity

106 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

12.8%

28 terminated out of 218 trials

Success Rate

79.1%

-7.4% vs benchmark

Late-Stage Pipeline

4%

9 trials in Phase 3/4

Results Transparency

39%

41 of 106 completed with results

Key Signals

41 with results79% success28 terminated

Data Visualizations

Phase Distribution

168Total
Not Applicable (85)
Early P 1 (9)
P 1 (33)
P 2 (32)
P 3 (9)

Trial Status

Completed106
Recruiting42
Terminated28
Unknown14
Active Not Recruiting13
Withdrawn9

Trial Success Rate

79.1%

Benchmark: 86.5%

Based on 106 completed trials

Clinical Trials (218)

Showing 20 of 20 trials
NCT07252739Phase 2RecruitingPrimary

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

NCT00505245Recruiting

New Assessment System in Measuring Symptom Distress in Cancer Patients

NCT04160390Active Not Recruiting

Blood Samples to Identify Biomarkers in Patients Treated With Cyclophosphamide After Donor Stem Cell Transplant

NCT03626285Unknown

Bone Marrow Transplantation Using CD34-Selected Stem Cells From Related or Unrelated Donors in Treating Participants With Cancer or Other Disorders

NCT06818643Phase 1Recruiting

A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)

NCT07600749Phase 1RecruitingPrimary

Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)

NCT07630974Phase 1RecruitingPrimary

A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01)

NCT06979596Phase 2RecruitingPrimary

A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015)

NCT06941272Phase 1RecruitingPrimary

A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01)

NCT07707999Early Phase 1Not Yet RecruitingPrimary

Clinical Application of FAP-Targeted Radionuclide Imaging in the Diagnosis and Staging of Malignant Solid Tumors

NCT01365169Not ApplicableRecruiting

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"

NCT07700758Phase 2Not Yet RecruitingPrimary

A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

NCT07302347Phase 1RecruitingPrimary

A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)

NCT04185935RecruitingPrimary

Molecular Genetics Studies of Cancer Patients and Their Relatives

NCT02479698Phase 2Recruiting

Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and/or JC Virus

NCT03367156Phase 2Active Not Recruiting

Dexamethasone in Controlling Dyspnea in Patients With Cancer

NCT01806129Not ApplicableActive Not RecruitingPrimary

Reproductive Health Program in Patients With Cancer

NCT07247110Phase 1RecruitingPrimary

A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)

NCT04014231CompletedPrimary

Novel Single Wave Assessment in Measuring Cardiac Dysfunction and Metabolic Syndrome in Patients With Cancer

NCT04181463Phase 2Not Yet RecruitingPrimary

Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer

Scroll to load more

Research Network

Activity Timeline